Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaun Tolan

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Leukemia & Lymphoma|April 10, 2008
Current treatment approaches for diffuse large B-cell lymphomaTim Illidge, Shaun Tolan
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Patient-specific PTV margins in radiotherapy for bladder cancer - a feasibility study using cone beam CTShaun Tolan, Vickie Kong, Tara Rosewall, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
Cancer|April 21, 2012
Utility of serum tumor markers during surveillance for stage I seminomaDanny Vesprini, Peter Chung, Shaun Tolan, et al.
European Urology|July 7, 2009
No role for routine chest radiography in stage I seminoma surveillanceShaun Tolan, Danny Vesprini, Michael A S Jewett, et al.
European Urology|September 12, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialNicholas van As, Binnaz Yasar, Clare Griffin, et al.
The Breast Journal|July 14, 2022
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World ExperienceBenjamin James Hall, Ajay Ashok Bhojwani, Helen Wong, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Leukemia & Lymphoma|April 10, 2008
Current treatment approaches for diffuse large B-cell lymphomaTim Illidge, Shaun Tolan
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Patient-specific PTV margins in radiotherapy for bladder cancer - a feasibility study using cone beam CTShaun Tolan, Vickie Kong, Tara Rosewall, et al.
Clinical and Translational Radiation Oncology|April 8, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicityRagu Ratnakumaran, Jonathan Mohajer, Samuel J Withey, et al.
Cancer|April 21, 2012
Utility of serum tumor markers during surveillance for stage I seminomaDanny Vesprini, Peter Chung, Shaun Tolan, et al.
European Urology|July 7, 2009
No role for routine chest radiography in stage I seminoma surveillanceShaun Tolan, Danny Vesprini, Michael A S Jewett, et al.
European Urology|September 12, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised TrialNicholas van As, Binnaz Yasar, Clare Griffin, et al.
The Breast Journal|July 14, 2022
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World ExperienceBenjamin James Hall, Ajay Ashok Bhojwani, Helen Wong, et al.
The Lancet. Oncology|June 15, 2025
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trialAlison C Tree, Victoria Hinder, Andrew Chan, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Pageof 2